Legacy recruits heavily to meet growing steriles demand
Company to reach 250 employees by year end to meet growing drug product manufacturing demand.
Legacy Pharmaceuticals it aims to increase headcount to 250 employees by year end to respond to the increasing demand in one-stop-shop drug products manufacturing services, as well as investing in its current assets.
Mike Danzi, Legacy CEO comments: “Being based in Basel we are fortunate to be able draw from a pool of highly educated and motivated staff - the region has in excess of 900 pharma and medtech companies employing over 50,000 people. This combination of motivation, skill and experience is key to successful project transfer success and will ensure we can support both present and future customers in their drive to succeed in the increasingly competitive biologics market.”
Legacy has been recruiting steadily during the year, enabling a move to third shifts in both semi solids and steriles, the restructuring of the engineering department, additional QA/validation/qualification resources and the expansion of the IT organisation.
“New employees tell us they value our breadth of products and the opportunities they have for further professional development. We actively encourage ownership of projects and creativity, while trying to foster a friendly supportive family environment. Because in the final analysis, spending money on new equipment and capacity means nothing if you do not have the right people to run it,” concludes Danzi.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...